PPD02.03 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Analysis of All Patients From VISION Cohorts A and C

Abstract

Tepotinib, a MET TKI, is approved for the treatment of METex14 skipping NSCLC. Here, we report analysis of all patients with METex14 skipping in the Phase II VISION study (Cohort A: >2-years’ follow-up; confirmatory Cohort C: >9-months’ follow-up); data cut-off February 20, 2022. Previously presented at WCLC 2022.